Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Bio-Rad Labs (BIO) PT Lowered to $400 at Citi
February 14, 2025 9:19 AM ESTCiti analyst Patrick Donnelly lowered the price target on Bio-Rad Labs (NYSE: BIO) to $400.00 (from $450.00) while maintaining a Buy rating.
The analyst comments "BIO guided core FY25 to grow +1.5-3.5% vs. consensus of +2.5%, with Life Sci at +1.5-3.5% vs. Dx at +2-3%. GM /... More
